How to buy Sigilon Therapeutics stock | 22 April

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Sigilon Therapeutics stock in Canada

Own Sigilon Therapeutics shares in just a few minutes.

Sigilon Therapeutics, Inc is a biotechnology business based in the US. Sigilon Therapeutics shares (SGTX.US) are listed on the NASDAQ and all prices are listed in US Dollars. Sigilon Therapeutics employs 99 staff and has a trailing 12-month revenue of around $13.4 million.

How to buy shares in Sigilon Therapeutics

  1. Choose a platform. If you're a beginner, our share-dealing table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: SGTX in this case.
  5. Research Sigilon Therapeutics shares. The platform should provide the latest information available.
  6. Buy your Sigilon Therapeutics shares. It's that simple.

Sigilon Therapeutics share price

Use our graph to track the performance of SGTX stocks over time.

Sigilon Therapeutics shares at a glance

Information last updated 2021-04-16.
Latest market close$N/A
52-week range$16.55 - $54.317
50-day moving average $22.8106
200-day moving average $30.1841
Wall St. target price$50.25
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Available asset types Stock Fee Option Fee Account Fee ETF Transaction Cost Feature Table description
Questrade
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
$4.95-$9.95
$9.95 + $1 per contract
$0
Free
$0 account fee and free ETF transactions.
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.
Interactive Brokers
Stocks, Bonds, Options, ETFs, Currencies, Futures
Min. $1.00, Max. 0.5% of trade value
$1.50 min. per order
$0 (if monthly commissions are greater than or equal to US$10.00)
Min. $1.00, Max. 0.5% of trade value
Extensive trading capabilities and global investment tracking.
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
Wealthsimple Trade
Stocks, ETFs
$0
N/A
$0
Free
Deposit and trade $100 and get a $25 bonus.
Pay no commissions when you trade Canadian stocks and ETFs with Wealthsimple Trade.
Qtrade Investor
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$6.95 - $8.75
$6.95 - $8.75 + $1.25 per contract
$0 if conditions met, otherwise $25/quarter
$0 - $8.75
Trade 100 ETFs free of charge.
Qtrade Investor offers low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options. Trade 100 ETFs free of charge and thousands more for $8.75 or lower.
Scotia iTRADE
Options, Mutual Funds, ETFs, GICs, International Equities
$4.99-$9.99
$9.99 + $1.25 contract ($4.99 + $1.25 contract if completed 150 trades or more a quarter)
$0
$9.99 ($4.99 if completed 150 trades or more a quarter)
Pay no annual account fees.
Buy, sell and trade ETFs, Equities, Options and more with competitive commissions.
loading

Compare up to 4 providers

Online stock trading

Is it a good time to buy Sigilon Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Sigilon Therapeutics financials

Revenue TTM USD$13.4 million
Gross profit TTM USD$-40,114,000
Return on assets TTM -20.86%
Return on equity TTM -68.72%
Profit margin 0%
Book value N/A
Market capitalisation USD$569.7 million

TTM: trailing 12 months

How to short and sell Sigilon Therapeutics shares

  1. Create a CFD or spread betting account.
  2. Search for the stock code. E.g. "SGTX.US"
  3. Choose your position size.
  4. Select "sell" rather than "buy".
  5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

There are currently 571,027 Sigilon Therapeutics shares held short by investors – that's known as Sigilon Therapeutics's "short interest". This figure is 176.9% up from 206,247 last month.

There are a few different ways that this level of interest in shorting Sigilon Therapeutics shares can be evaluated.

Sigilon Therapeutics's "short interest ratio" (SIR)

Sigilon Therapeutics's "short interest ratio" (SIR) is the quantity of Sigilon Therapeutics shares currently shorted divided by the average quantity of Sigilon Therapeutics shares traded daily (recently around 190342.33333333). Sigilon Therapeutics's SIR currently stands at 3. In other words for every 100,000 Sigilon Therapeutics shares traded daily on the market, roughly 3000 shares are currently held short.

However Sigilon Therapeutics's short interest can also be evaluated against the total number of Sigilon Therapeutics shares, or, against the total number of tradable Sigilon Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Sigilon Therapeutics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Sigilon Therapeutics shares in existence, roughly 20 shares are currently held short) or 0.0343% of the tradable shares (for every 100,000 tradable Sigilon Therapeutics shares, roughly 34 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Sigilon Therapeutics.

Find out more about how you can short Sigilon Therapeutics stock.

Sigilon Therapeutics share dividends

We're not expecting Sigilon Therapeutics to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.

Sigilon Therapeutics overview

Sigilon Therapeutics, Inc., a biopharmaceutical company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate-severe to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of the disease in patients with mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 designed to replace islet cells for the treatment of type 1 diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site